|
Associate Director, Global Medical Affairs, Neuroscience - Raritan New Jersey
Company: Disability Solutions Location: Raritan, New Jersey
Posted On: 05/03/2024
Janssen Research & Development, L.L.C., a division of Johnson & Johnson's Family of Companies is recruiting for an Associate Director, Global Medical Affairs, Neuroscience located in Raritan, NJ. At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at The Associate Director, Global Medical Affairs, for neuroscience will be responsible for leading aspects of the clinical-commercial optimization for a late-stage neurodegeneration asset development and life cycle management strategies and plans under the guidance of the Global Medical Affairs Leader (GMAL) within the Neuroscience therapeutic area (TAs). S/he will partner closely with Commercial, Market Access and Medical teams at a Global and Regional level as well as supporting the Compound Development Team to develop an integrated global medical affairs strategies and plans. The Medical Advisor will support and partner with the GMAL on the global publication plans, global opinion leader relations, global medical education and global or regional advisory boards for a late-stage neurology asset and other TA products starting in early development (phase IIA) and through launch of major life cycle management initiatives. Responsibilities include: - Partnering with the GMAL in developing global medical affairs strategy and plan for the compound based on prioritized regional needs.
- Work with the CDT and GMAL to ensure integration with the overall global compound strategy, resulting in one global R&D and Medical Affairs compound development plan
|
|